Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2017	Mar. 01, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Trading Symbol	RKDA
Entity Registrant Name	ARCADIA BIOSCIENCES, INC.
Entity Central Index Key	0001469443
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,136,031
Entity Public Float			$ 4,900,000

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 9,125	$ 2,013
Short-term investments	3,898	48,547
Accounts receivable	1,231	349
Unbilled revenue	4	184
Inventories — current	229	252
Prepaid expenses and other current assets	560	877
Total current assets	15,047	52,222
Property and equipment, net	299	508
Inventories — noncurrent	1,168	1,327
Long-term investments		2,498
Other noncurrent assets	56	19
Total assets	16,570	56,574
Current liabilities:
Accounts payable and accrued expenses	2,496	2,359
Amounts due to related parties	29	30
Unearned revenue — current	1,000	740
Total current liabilities	3,525	3,129
Notes payable		25,127
Unearned revenue — noncurrent	2,038	3,120
Other noncurrent liabilities	3,000	3,000
Total liabilities	8,563	34,376
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 and 400,000,000 shares authorized as of December 31, 2017 and December 31, 2016; 2,134,154 and 2,224,384 shares issued and outstanding as of December 31, 2017 and December 31, 2016, respectively.	42	44
Additional paid-in capital	175,223	173,723
Accumulated deficit	(167,257)	(151,550)
Accumulated other comprehensive loss	(1)	(19)
Total stockholders’ equity	8,007	22,198
Total liabilities and stockholders’ equity	$ 16,570	$ 56,574

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	400,000,000
Common stock, issued	2,134,154	2,224,384
Common stock, outstanding	2,134,154	2,224,384

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Product	$ 514,000	$ 669,000
License	1,470,000	144,000
Contract research and government grants	2,042,000	2,375,000
Total revenues	4,026,000	3,188,000
Operating expenses:
Cost of product revenues	283,000	895,000
Research and development	7,407,000	8,663,000
Selling, general and administrative	10,651,000	12,250,000
Total operating expenses	18,341,000	21,808,000
Loss from operations	(14,315,000)	(18,620,000)
Interest expense	(747,000)	(1,319,000)
Other income, net	281,000	340,000
Loss on extinguishment of debt	(900,000)
Net loss before income taxes	(15,681,000)	(19,599,000)
Income tax provision	(26,000)	(25,000)
Net loss attributable to common stockholders	$ (15,707,000)	$ (19,624,000)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (7.28)	$ (8.85)
Weighted-average number of shares used in per share calculations:
Basic and diluted	2,156,201	2,218,341
Other comprehensive income, net of tax
Unrealized gains on available-for-sale securities	$ 18,000	$ 96,000
Other comprehensive income	18,000	96,000
Comprehensive loss attributable to common stockholders	$ (15,689,000)	$ (19,528,000)

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2015	$ 40,225	$ 44	$ 172,222	$ (131,926)	$ (115)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2015		2,209,210
Exercise of stock options	$ 270		270
Exercise of stock options, Shares	11,407	11,407
Issuance of shares related to employee stock purchase plan	$ 172		172
Issuance of shares related to employee stock purchase plan, Shares		3,767
Stock-based compensation	1,059		1,059
Other comprehensive income	96				96
Net loss	(19,624)			(19,624)
Stockholders Equity, Ending Balance at Dec. 31, 2016	$ 22,198	$ 44	173,723	(151,550)	(19)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2016		2,224,384
Exercise of stock options, Shares	0
Issuance of shares related to employee stock purchase plan	$ 24		24
Issuance of shares related to employee stock purchase plan, Shares		1,964
Stock-based compensation	1,474		1,474
Other comprehensive income	18				18
Exchange of membership interest in unconsolidated entity for common stock	0	$ (2)	2
Exchange of membership interest in unconsolidated entity for common stock, Shares		(92,194)
Net loss	(15,707)			(15,707)
Stockholders Equity, Ending Balance at Dec. 31, 2017	$ 8,007	$ 42	$ 175,223	$ (167,257)	$ (1)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2017		2,134,153

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (15,707,000)	$ (19,624,000)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	279,000	304,000
(Gain) Loss on disposal of equipment	(1,000)	4,000
Net amortization of investment premium and discount	(89,000)	140,000
Loss on sale of investments	2,000
Stock-based compensation	1,474,000	1,059,000
Accretion of debt discount	98,000	198,000
Loss on extinguishment of debt	900,000
Changes in operating assets and liabilities:
Accounts receivable	(882,000)	357,000
Unbilled revenue	179,000	(102,000)
Inventories	183,000	582,000
Prepaid expenses and other current assets	324,000	(185,000)
Other noncurrent assets	11,000	5,000
Accounts payable and accrued expenses	87,000	(19,000)
Amounts due to related parties	(1,000)	11,000
Unearned revenue	(822,000)	215,000
Net cash used in operating activities	(13,965,000)	(17,055,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment	4,000
Purchases of property and equipment	(79,000)	(231,000)
Purchases of investments	(19,405,000)	(41,385,000)
Proceeds from sales and maturities of investments	66,658,000	36,315,000
Net cash provided by (used in) investing activities	47,178,000	(5,301,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of debt issuance costs		(46,000)
Payments of debt extinguishment costs	(1,125,000)
Payments on notes payable	(25,000,000)
Proceeds from exercise of stock options and purchases through ESPP	24,000	442,000
Net cash (used in) provided by financing activities	(26,101,000)	396,000
Net increase (decrease) in cash and cash equivalents	7,112,000	(21,960,000)
Cash and cash equivalents — beginning of period	2,013,000	23,973,000
Cash and cash equivalents — end of period	9,125,000	2,013,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	746,000	1,033,000
Cash paid for income taxes	2,000	$ 29,000
NONCASH INVESTING AND FINANCING ACTIVITIES:
Exchange of membership interest in unconsolidated entity for common stock	2,000
Proceeds from sale of fixed assets included in prepaid expenses and other current assets	7,000
Deferred financing costs in accounts payable and accrued expenses	$ 50,000

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2017
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business Organization Arcadia Biosciences, Inc. (the "Company"), was incorporated in the state of Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, and American Falls, Idaho. The Company was reincorporated in Delaware in March 2015. The Company is a consumer-driven, agricultural food ingredient company. We aim to create value across the agricultural production and supply chain beginning with enhanced crop productivity for farmers and ultimately delivering accelerated innovation in nutritional quality consumer foods. We use state of the art gene-editing technology and advanced breeding techniques to naturally enhance the nutritional quality of grains and oilseeds to address the rapidly evolving trends in consumer health and nutrition. In addition, we have developed a broad pipeline of high value crop productivity traits designed to enhance farmer economics. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 7), which is jointly owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca, which is consolidated by the Company, was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. Reverse Stock Split In January 2018, the Company’s board of directors approved a reverse split of 1:20 on the Company’s issued and outstanding common stock. In January 2018, the Company’s stockholders approved the certificate of amendment, which the Company filed on January 23, 2018 with the Secretary of State of Delaware to effect the reverse split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statement have been retroactively adjusted to reflect the reverse stock split for all periods presented. Liquidity, Capital Resources, and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2017, the Company had an accumulated deficit of $167.3 million, cash and cash equivalents of $9.1 million, and short-term investments of $3.9 million. As is disclosed in Note 10, the Company repaid its $25.0 million term loan and related interest, prepayment and end-of-term payments totaling $1.3 million with Silicon Valley Bank in July 2017. The Company believes that its existing cash, cash equivalents and investments will be insufficient to meet its anticipated cash requirements for at least through March 2019, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans include attempting to secure additional funding through equity or debt financings, sales or out-licensing of intellectual property assets, seeking partnerships with other agriculture biotechnology companies or third parties to co-develop and fund research, development or commercialization efforts, or similar transactions. There is no assurance that the Company will be successful in obtaining the necessary funding to meet its business objectives.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The consolidated financial statements include the accounts of the Company and Verdeca LLC. All intercompany balances and transactions have been eliminated in consolidation. The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP (“GAAP”), and with the rules of the Securities and Exchange Commission. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. The Company evaluates its relationships with the VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Verdeca LLC has no operations, assets or liability as of and for the years ended December 31, 2017 and 2016.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company’s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of the provision for income taxes, costs to complete government grants and research contracts, net realizable value of inventory, and the development period of revenue-generating technologies. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers any liquid investments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks. The Company limits cash investments to financial institutions with high credit standings; therefore, management believes that there is no significant exposure to any credit risk in the Company’s cash and cash equivalents. However, as of December 31, 2017 and 2016, a substantial portion of the Company’s cash in depository accounts is in excess of the federal deposit insurance limits.

Investments in Equity and Debt Securities

The Company uses the equity method to account for investments in equity securities if the investment provides the Company the ability to exercise significant influence over operating and financial policies of the investee. The Company includes its proportionate share of earnings and/or losses of the equity method investee in its Consolidated Statements of Operations and Comprehensive Loss. The carrying value of the equity investments is reported using the equity method in the Consolidated Balance Sheets. As of December 31, 2017 and 2016, the Company’s investment in Limagrain Cereal Seeds LLC (“LCS”) is $0. See Note 6 – Investments in Unconsolidated Entity for additional information.

Investments in equity securities in which the Company holds less than 20% voting interest and on which the Company does not have the ability to exercise significant influence, and do not have readily determinable fair values are accounted for under the cost method. Cost method investments are originally recorded at cost and are reported on the Consolidated Balance Sheets.

Investments in debt securities are carried at fair value and classified as available-for-sale. Realized gains and losses on available-for-sale securities are included in other income (loss) — net in the Consolidated Statements of Operations and Comprehensive Loss. Unrealized gains and losses, net of deferred taxes, on available-for-sale securities are included in the Consolidated Balance Sheets as a component of accumulated other comprehensive income (loss) ("AOCI”). Securities classified as available-for-sale are reported as cash and cash equivalent, short-term investments or long-term investments in the Consolidated Balance Sheets based on the nature of the investments and maturity period. Short-term investments have maturities of less than a year and long-term investments have maturities of a year and greater from the balance sheet date. The Company’s debt securities are primarily comprised of U.S. government securities, U.S. government agency securities, commercial paper, certificates of deposit, and money markets. These available-for-sale investments are held in the custody of a major financial institution.

Other-than-Temporary Impairments on Investment

The Company regularly reviews each of its investments for impairment by determining if the investment has sustained an other-than-temporary decline in its value, in which case the investment is written down to its fair value by a charge to earnings. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the investment in relation to its cost basis, (ii) the financial condition of the investment, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery of the market value of the investment. As of December 31, 2017 and 2016, there was no impairment of the Company’s investments.

Accounts Receivable

Accounts receivable represents amounts owed to the Company from product sales, licenses and contract research and government grants. The carrying value of the Company’s receivables represents estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is recorded accordingly. Past-due receivable balances are written off when the Company’s internal collection efforts have been unsuccessful in collecting the amounts due. The Company had no amounts reserved for doubtful accounts at December 31, 2017 and 2016 as the Company expected full collection of the accounts receivable balances as of each of these dates.

SONOVA® Gamma Linolenic Acid (“GLA”) Safflower Oil Inventory

Proprietary safflower plants are grown, producing seed with a high-GLA content. This seed is used for subsequent plantings or processed, and sold as GLA oil, including SONOVA 400 GLA safflower oils and SONOVA Ultra GLA safflower oil, which we refer to as our SONOVA products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops and costs to process and store harvested seed. Inventory costs are tracked on a lot-identified basis and are included as cost of product revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write downs to inventory are based upon estimates about future demand from the Company’s customers and distributors and market conditions.

The inventories—current line item in the balance sheet consists of the cost of oil inventory forecasted to be sold in the next 12 months, as of the balance sheet date. The inventories—noncurrent line item consists of oil and seed inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date.

Raw materials inventories consist primarily of seed production costs incurred by our contracted cooperators. Finished goods inventories consist of GLA oil that is available for sale. The Company recorded a $0.5 million write-down of inventory for the year ended December 31, 2016. A write-down was not recorded for the year ended December 31, 2017. Inventories consist of the following (in thousands):

	As of December 31,
	2017		2016
Raw Materials	$	45	$	44
Finished Goods		1,352		1,535
Inventories	$	1,397	$	1,579

Property and Equipment

Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets:

	Years
Laboratory equipment	5
Software and computer equipment	3
Furniture and fixtures	7
Vehicles	5
Leasehold improvements	2-10	*

*	Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.

Impairment of Long-Lived Assets

The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value. As of December 31, 2017 and 2016, there was no impairment of the Company’s long-lived assets.

Fair Value of Financial Instruments

Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows:

•

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

•

Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 inputs are unobservable inputs for the asset or liability.

Concentration of Risk

Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties.

Customer Concentration

Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date.

Customers representing greater than 10% of accounts receivable were as follows (in percentages):

	As of December 31,
	2017		2016
Customer A		18		—
Customer D		53		—
Customer E		24		36
Customer H		—		27
Customer I		—		22

Customers representing greater than 10% of total revenues were as follows (in percentages):

	For Year Ended December 31,
	2017		2016
Customer A		26		—
Customer D		18		30
Customer G		2		21
Customer J		8		11
Customer K		14		—

Stock-Based Compensation

The Company recognizes compensation expense related to employee stock purchase plan and the cost of stock-based compensation awards made to employees and directors on a straight-line basis over the requisite service period, net of estimated forfeitures. Judgment is required in estimating the amount of stock-based awards that will be forfeited prior to vesting. Compensation expense could be revised in subsequent periods if actual forfeitures differ from those estimates. The Company has selected the Black-Scholes option-pricing model and various inputs to estimate the fair value of its stock-based awards. See Note 11 for additional information.

The Company accounts for compensation expense related to stock options granted to non-employees based on the fair values estimated using the Black-Scholes model. Stock options granted to non-employees are re-measured at each reporting date until the award is vested.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

Net Loss per Share

Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses.

Revenue Recognition

Revenue is generated through product sales, license agreements, contract research agreements, and government grants. The Company recognizes revenue when the following criteria have been met: persuasive evidence of an arrangement with the customer exists; price and terms of the arrangement are fixed or determinable; delivery of the product has occurred or the service has been performed in accordance with the terms of the arrangement; and collectability is reasonably assured.

For revenue agreements with multiple-element arrangements, such as license and contract agreements, the Company analyzes the arrangements to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. This determination is generally based on whether any deliverable has stand-alone value to the customer. This analysis also establishes a selling price hierarchy for determining how to allocate arrangement consideration to identified units of accounting. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price method and the appropriate revenue recognition principles are applied to each unit. The selling price used for each unit of accounting is based on estimated selling price as neither vendor-specific nor third-party evidence is available. When the Company determines that an arrangement should be accounted for as a single unit of accounting, it must determine the period over which the performance obligations will be performed and revenue will be recognized over the performance period.

Product Revenues

Product revenues consist of sales of our SONOVA products. Product revenues are recognized once passage of title has occurred, contractually specified acceptance criteria have been met, and all other revenue recognition criteria have been met. Shipping and handling costs charged to customers are recorded as revenues and included in cost of product revenues at the time the sale is recognized.

License Revenues

The Company’s license agreements generally include up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments. Upon commercialization of a product utilizing a licensed technology, the Company receives certain value-sharing payments associated with the incremental revenue attributable to the licensed technology.

The Company has determined that, at the inception of each license agreement, there is only one deliverable for the license for and access to the specified intellectual property. The up-front nonrefundable license fees are recognized as revenue proportionally over the development period. The development period is estimated based upon factors such as type of traits, nature of crops and geographies, which are used to establish the initial deferral period. The Company continually reviews such estimates based on progress toward product commercialization and performs a thorough analysis at least annually. If the deferral period estimate changes, the amount of revenue recognized during the period is either accelerated or reversed to reflect the updated deferred balances as of the current period-end, capturing the cumulative effect of the changes. The annual license fees are payable at the end of the annual period and such fees typically are not required to be paid if the agreement is cancelled prior to the due date. Therefore, annual license fees are only recognized when they become due. In the event a license is terminated prior to commercialization, the deferred balance of the unamortized up-front license is released to revenue on the effective date.

The Company’s license agreements generally include contingent milestone payments in the development life cycle of the related technology, such as achievement of specific technological targets, successful results from field trials, filing for approval with regulatory agencies, approvals granted by regulatory agencies and commercial launch of a product utilizing the licensed technology. The Company evaluates whether each milestone is substantive and at risk at the time the agreement is executed. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (i) the entity’s performance to achieve the milestone or (ii) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone; (b) the consideration relates solely to past performance; and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company generally considers non-refundable milestones that the Company expects to be achieved as a result of the Company’s efforts during the period of the Company’s performance obligations under the license agreement to be substantive and recognizes them as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met.

Once a product containing one or more of the Company’s traits is commercialized, the Company is entitled to receive a portion of the incremental revenue that the trait generates for its commercial partner. These value-sharing payments will be recorded on the accrual basis when results are reliably measurable, collectability is reasonably assured, and all other revenue recognition criteria are met. None have been received to date.

Contract Research Revenues

Contract research revenues consist of amounts earned from performing contracted research activities for third parties. Activities performed are related to breeding programs or the genetic engineering of plants and are subject to an executed agreement. Generally, fees for research and development activities are recognized as the services are performed over the performance period, as specified in the respective agreements, assuming all other revenue recognition criteria are met.

Similar to the license agreements, under the contract research agreements, once a product containing one or more of the Company’s traits is commercialized, the Company is entitled to receive a portion of the incremental revenue that the trait generates for its commercial partner. These value-sharing payments will be recorded on the accrual basis when results are reliably measurable, collectability is reasonably assured, and all other revenue recognition criteria are met.

Government Grant Revenues

Based on the terms of the government grant, the Company recognizes revenue from payments received from government entities for research and development activities over a contractually defined period. Revenues from government grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the government grants were provided have been met.

Unearned Revenue

The Company defers revenue to the extent that cash received in conjunction with a license agreement, contract or grant exceeds the revenue recognized in accordance with Company policies.

Research and Development Expenses

Research and development expenses consist of costs incurred in the discovery, development, and testing of the Company’s product candidates. These expenses consist primarily of employee salaries and benefits, including stock-based compensation, fees paid to subcontracted research providers, fees associated with in-licensing technology, royalty agreements, land leased for field trials, chemicals and supplies and other external expenses. These costs are expensed as incurred. Additionally, as disclosed in Note 12, the Company is required from time to time to make certain milestone payments in connection with the development of technologies. These milestone payments are expensed at the time the milestone is achieved and deemed payable.

Recent Accounting Pronouncements

12 Months Ended

Dec. 31, 2017

Accounting Changes And Error Corrections [Abstract]

Recent Accounting Pronouncements

Note 3. Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date, which defers the effective date of ASU No. 2014-09 by one year allowing early adoption as of the original effective date January 1, 2017. The deferral results in the new revenue standard being effective for the Company January 1, 2018. Additional ASUs have been issued to amend or clarify the new guidance in ASC Topic 606 as follows:

•

ASU No. 2016-08 Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) was issued in March 2016. ASU No. 2016-08 requires an entity to determine whether the nature of its promise to provide goods or services to a customer is performed in a principal or agent capacity and to recognize revenue in a gross or net manner based on its principal or agent designation.

•

ASU No. 2016-10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing was issued in April 2016. ASU No. 2016-10 addresses implementation issues identified by the FASB-International Accounting Standards Board Joint Transition Resource Group for Revenue Recognition concerning identifying performance obligations and accounting for licenses of intellectual property.

•

ASU No. 2016-12 Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients was issued in May 2016. ASU No. 2016-12 amends the new revenue recognition standard to clarify the guidance on assessing collectability, measuring noncash consideration, presenting sales taxes and certain transition matters.

•

ASU No. 2016-20 Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers was issued in December 2016. ASU No. 2016-20 provides additional clarification on 13 issues or corrects unintended application of FASB Accounting Standards Codification (Topic 606).

The standard permits the use of either the retrospective or cumulative effect transition method. The Company is analyzing the impacts of the new revenue standards with the assistance of a third-party professional services firm. The Company adopted the requirements of the new standard in the first quarter of 2018 using the modified retrospective method with the likely impact per revenue stream as follows:

•

Product Revenue – the Company believes there will not be an impact. Product revenues comprise of a single performance obligation for the delivery of goods for which transfer of control occurs at the shipping point.

•

Grant and Contract Research Revenue – the Company believes there will not be an impact. Grant and contract research revenue will continue to be accounted for as a single performance obligation for which revenues are recognized over time using the input method (e.g. costs incurred to date relative to the total estimated costs at completion).

•

License Agreement Revenue – the Company believes there will be an impact. The Company believes its license agreements are licenses of functional intellectual property consisting of a single performance obligation. A functional license requires point in time revenue recognition, which may impact this revenue stream. This is primarily due to the various payment terms of the license agreements:

Up-front license fees – the Company believes there will be a significant impact. The up-front fees will be recognized at a point in time rather than over the estimated commercialization period. The balances of unearned revenues on the balance sheet totaling $2.4 million related to up-front license fees and any associated deferred tax assets are expected to be derecognized through an opening adjustment to retained earnings on January 1, 2018. The Company believes new license agreements executed in 2018 will have up-front license fees recognized as revenue upon execution of the agreement.

Annual license fees – the Company believes there will be an impact; however, no adjustment is required upon adoption. Annual license fees will be variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company will need to design and implement a process to assess when renewal of annual license fees are probable in order to determine the timing of revenue recognition for annual license fees.

Milestone fees – the Company believes there will be an impact; however, no adjustment is required upon adoption. Milestone fees will be variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company will need to design and implement a process to assess when achievement of milestones are probable in order to determine the timing of revenue recognition for milestone fees.

Commercial Value Sharing Fees – the Company believes there will not be an impact to revenue recognition as no license agreements within our portfolio have commercialized; however, no adjustment is required upon adoption. Commercial value share fees will be recognized based on subsequent sales by the licensee.

Internal Revenue Service rules currently allow for a one-year deferral of revenue on cash receipts, which the Company has taken. Upon adoption of Topic 606, tax recognition will follow book recognition for up-front and commercial value sharing fees. Annual license fees and milestone fees may continue to be recognized differently for book and tax to the extent that revenue recognized for book is prior to cash receipts.

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The amendments in this update impacts classification, additional fair value measurement, impairment assessment of equity investments and current required disclosures. This standard is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted if the entity meets certain early application guidance. The Company is evaluating the impact of the adoption of ASU No. 2016-01 on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Based on the new standard, lessees would recognize lease assets and lease liabilities for those leases classified as operating leases under previous GAAP. The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early application is permitted. The Company is evaluating the impact of the adoption of ASU No. 2016-02 on its consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is evaluating the impact of the adoption of ASU No. 2016-13 on its consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The amendments address cash flow issues such as debt prepayment or debt extinguishment costs and zero-coupon debt instruments. The amendments in this update are effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. The amendments are to be applied using a retrospective transition method to each period presented. If it is impractical to retrospectively apply, it can be applied prospectively as of the earliest date practicable. The Company is evaluating the impact of the adoption of ASU No. 2016-15 on its consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting. The amendments affect any entity that changes the terms or conditions of a share-based payment award. The amendments in this update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period for public business entities for reporting periods for which financial statements have not yet been issued and be applied prospectively to an award modified on or after the adoption date. The Company is currently evaluating the impact of the adoption of ASU No. 2017-09 on its consolidated financial statements.

In November 2017, the FASB issued ASU No. 2017-14, Income Statement—Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), and Revenue from Contracts with Customers (Topic 606) (SEC Update). The ASU amends SEC paragraphs pursuant to the SEC Staff Accounting Bulletin No. 116 and SEC Release No. 33-10403, which bring existing guidance into conformity with Topic 606, Revenue from Contracts with Customers. The amendments were effective upon issuance. The Company is currently evaluating the impact on revenue recognition, however it does not expect these amendments to have a material effect on its financial statements.

Property and Equipment, Net

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Property and Equipment, Net

Note 4. Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	As of December 31,
	2017			2016
Laboratory equipment	$	2,404		$	2,632
Software and computer equipment		424			449
Furniture and fixtures		147			153
Vehicles		203			204
Leasehold improvements		2,002			1,991
Assets under construction		—			20
Property and equipment, gross		5,180			5,449
Less accumulated depreciation and amortization		(4,881	)		(4,941	)
Property and equipment, net	$	299		$	508

Depreciation and amortization expense is $279,000 and $304,000 for the years ended December 31, 2017 and 2016, respectively.

Investments and Fair Value Measurements

12 Months Ended

Dec. 31, 2017

Investments And Fair Value Measurements [Abstract]

Investments and Fair Value Measurements

Note 5. Investments and Fair Value Measurements

Available-for-Sale Investments

The Company classified short-term and long-term investments as “available-for-sale.” Investments are free of trading restrictions. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses, net of taxes, are included in accumulated other comprehensive loss, which is reflected as a separate component of stockholder’s equity in the Consolidated Balance Sheets. Gains and losses are recognized when realized in the Consolidated Statements of Operations and Comprehensive Loss.

The following tables summarize the amortized cost and fair value of the available-for-sale investment securities portfolio at December 31, 2017 and December 31, 2016, and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income (“AOCI”):

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
December 31, 2017
Cash equivalents:
Money market funds	$	8,943	$	—	$	—		$	8,943
Short-term investments:
Commercial paper		1,399		—		—			1,399
U.S. government securities		2,500		—		(1	)		2,499
Total Assets at Fair Value	$	12,842	$	—	$	(1	)	$	12,841

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
December 31, 2016
Cash equivalents:
Money market funds	$	1,549	$	—	$	—		$	1,549
Short-term investments:
Certificates of Deposit		3,049		—		(2	)		3,047
Commercial paper		21,248		—		—			21,248
U.S. government securities		19,267		—		(9	)		19,258
U.S. government agency securities		5,000		—		(6	)		4,994
Long-term investments:
U.S. government securities		2,500		—		(2	)		2,498
Total Assets at Fair Value	$	52,613	$	—	$	(19	)	$	52,594

The Company did not have any investment categories that were in a continuous unrealized loss position for more than twelve months as of December 31, 2017.

As of December 31, 2017, for fixed income securities that were in unrealized loss positions, the Company has determined that (i) it does not have the intent to sell any of these investments, and (ii) it is not more likely than not that it will be required to sell any of these investments before recovery of the entire amortized cost basis. The Company anticipates that it will recover the entire amortized cost basis of such fixed income securities and has determined that no other-than-temporary impairments associated with credit losses were required to be recognized during the year ended December 31, 2017.

Fair Value Measurement

The fair value of the available-for-sale investments at December 31, 2017 were as follows:

	Fair Value Measurements at December 31, 2017
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	8,943	$	—	$	—	$	8,943
Short-term investments:
Commercial paper		—		1,399		—		1,399
U.S. government securities		2,499		—		—		2,499
Total Assets at Fair Value	$	11,442	$	1,399	$	—	$	12,841

The fair value of the available-for-sale investments at December 31, 2016 were as follows:

	Fair Value Measurements at December 31, 2016
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	1,549	$	—	$	—	$	1,549
Short-term investments:
Certificates of Deposit		—		3,047		—		3,047
Commercial paper		—		21,248		—		21,248
U.S. government securities		19,258		—		—		19,258
U.S. government agency securities		—		4,994		—		4,994
Long-term investments:
U.S. government securities		2,498		—		—		2,498
Total Assets at Fair Value	$	23,305	$	29,289	$	—	$	52,594

The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2017 or 2016. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and debt instruments. For accounts receivable, accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of December 31, 2017 and 2016 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The carrying values of long-term debt, which approximate fair value, and debt instruments are principally measured using Level 2 inputs based on quoted market prices or pricing models using current market rates.

Investment in Unconsolidated Entity

12 Months Ended

Dec. 31, 2017

Equity Method Investments And Joint Ventures [Abstract]

Investment in Unconsolidated Entity

Note 6. Investment in Unconsolidated Entity

Limagrain Cereal Seeds LLC

At December 31, 2016, the Company owned a 35% ownership position in Limagrain Cereal Seeds LLC (“LCS”). The remaining 65% of LCS was owned by Vilmorin & Cie (“Limagrain”), a major global producer and marketer of field crop and vegetable seeds, through its wholly owned subsidiary, Vilmorin USA (“VUSA”). LCS improves and develops new wheat and barley varieties utilizing genetic and breeding resources, as well as advanced technologies, from Limagrain and the Company. Historically, funding for LCS has come from an initial pro rata equity investment from each partner and with subsequent financing in the form of debt from VUSA. As of December 31, 2016, the Company’s investment in LCS had been reduced to $0 as a result of its equity method loss recognition.

On March 31, 2017, the Company and VUSA entered into a non-cash exchange agreement, which the Company transferred to VUSA the Company’s entire membership interest in LCS and VUSA transferred to the Company 92,194 shares of the Company’s common stock held by Limagrain. The Company recorded the retirement of the shares using the cost method, resulting in an equity reclassification between common stock par value and additional paid-in capital.

As of December 31, 2017, the Company does not have an investment in an unconsolidated entity.

Summarized condensed financial information related to the unconsolidated entity, accounted for using the equity method is as follows (in thousands):

	As of and for the year ended December 31,
	2017 (3)			2016
Assets:
Current assets	$	—		$	2,963
Non-current assets		—			9,776
Total assets		—			12,739
Liabilities and equity:
Current liabilities		—			26,992
Equity of Arcadia Biosciences, Inc.(1)		—			(4,989	)
Equity of VUSA		—			(9,264	)
Total liabilities and equity	$	—		$	12,739
Revenue	$	216		$	3,635
Gross profit		118			1,594
Loss from continuing operations		(1,422	)		(5,268	)
Net loss (2)		(1,539	)		(5,413	)

(1)	Effective June 2014, the investment balance was reduced to $0.

(2)	As the Company’ investment balance was reduced to $0 in 2014, the Company’s share of the pretax loss is $0 for the years ended December 31, 2017 and 2016.

(3)	Represents year to date activity through transaction date of March 31, 2017.

Variable Interest Entity	12 Months Ended
Variable Interest Entity	Dec. 31, 2017
Equity Method Investments And Joint Ventures [Abstract]
Variable Interest Entity	Note 7. Variable Interest Entity In February 2012, the Company formed Verdeca LLC (“Verdeca”), which is equally owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative owned by approximately 300 shareholders, including some of South America’s largest soybean growers. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. Both the Company and Bioceres incur expenses in support of specific activities agreed, as defined by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. An agreement executed in conjunction with the formation of Verdeca specified that if Bioceres determines it requires cash to fund its contributed services (subject to certain annual limits), Bioceres, S.A. may elect to sell shares of its common stock to the Company for an amount not exceeding $5.0 million in the aggregate over a four-year period. The Company determined that its commitment to purchase common stock in Bioceres, S.A. as a means to provide capital to Verdeca resulted in a de facto agency relationship between the Company and Bioceres. The Company considers qualitative factors in assessing the primary beneficiary which include understanding the purpose and design of the VIE, associated risks that the VIE creates, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it is the primary beneficiary of Verdeca. As a result of the agreement to fund future contributions by Bioceres, the Company purchased common stock of Bioceres, S.A. in the aggregate amount of $2.0 million between January 2013 and August 2014. The Company’s maximum commitment to purchase stock in Bioceres, S.A. under the original funding agreement amounted to $2.0 million for 2014 and $1.2 million for 2015. In September 2014, the Company and Bioceres, S.A. entered into an agreement to reduce the annual commitment for 2014 to $500,000 and to eliminate the 2015 commitment. In consideration for these amendments, the Company surrendered 1,832 shares of Bioceres, S.A. held by the Company. The Company recorded a research and development expense of $1.5 million related to this agreement during the year ended December 31, 2014. In addition, the Company had a right to require Bioceres, S.A. to repurchase any shares of common stock then owned by the Company upon the occurrence of certain events specified in the agreement, and similarly, Bioceres, S.A. had the right to require the Company to sell back any shares of common stock owned by the Company under certain circumstances. The Company entered into a subcontracted research agreement in 2015 with Bioceres S.A. and Bioceres Semillas, S.A., a subsidiary of Bioceres S.A. Per the agreement, the Company could pay for these services with a combination of cash and Bioceres S.A. shares. In 2015, the liability for the aforementioned agreement was settled with $205,000 of cash and the remaining 632 Bioceres S.A. shares, with a fair value of $500,000, held by the Company, thus reducing the cost investment on the Company’s Consolidated Balance Sheet to $0. Under the terms of the joint development agreement, the Company has incurred direct expenses and allocated overhead in the amount of $912,000 and $416,000 for the years ended December 31, 2017 and 2016, respectively.

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Accounts Payable and Accrued Expenses

Note 8. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following (in thousands):

	As of December 31,
	2017		2016
Accounts payable—trade	$	366	$	222
Payroll and benefits		805		1,331
Research and development		899		182
Royalty fees due to unrelated parties		177		170
Accrued interest on notes payable		—		98
Consulting		32		29
Rent and utilities		51		85
Legal		83		45
Accrued withholding taxes		24		—
Other		59		197
Total accounts payable and accrued expenses	$	2,496	$	2,359

Exit or Disposal Activities

As of December 2016, the Company completed a comprehensive strategic review of its technology programs, pipeline, partner program progress, competitive landscape and market conditions, which resulted in the decision to realign its organizational capabilities to best support the Company’s near term product commercialization needs and preserve cash. As a result, a number of personnel changes were made, including the elimination of 23 positions. The severance costs associated with this reduction in force were $192,000 for one-time employee termination benefits, and $224,000 in severance costs in connection with an executive employment contract, both of which, are recorded in Selling, General, and Administrative expense for the year ended December 31, 2016. A portion of the one-time employee termination benefits was paid out in December 2016 and the remaining severance amount of $389,000 was accrued under payroll and benefits as of December 31, 2016 and paid in 2017. Additionally, the Company closed its Seattle office in March 2017. The Company has no other associated exit or disposal costs pertaining to the years ended December 31, 2017 and 2016.

Collaborative Arrangements	12 Months Ended
Collaborative Arrangements	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Arrangements	9. Collaborative Arrangements In August 2017, the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with a third party and involves a joint operating activity where both Arcadia and the third party are active participants in the activities of the collaboration. Arcadia and the third party participate in the research and development, and Arcadia has the primary responsibility for the intellectual property strategy while the third party will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success. The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development, which states R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results are achieved.

Long-Term Debt and Other Financing Arrangements

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Long-Term Debt and Other Financing Arrangements

Note 10. Long-Term Debt and Other Financing Arrangements

There was no long-term debt as of the year ended December 31, 2017. Longterm debt as of the year ended December 31, 2016 consisted of the following (in thousands):


Notes payable	$	25,127
Total	$	25,127
Less current portion		—
Long-term portion	$	25,127

Term Loan

In December 2015, the Company entered into a loan and security agreement (“Term Loan”) with Silicon Valley Bank (the “Bank”) providing for a senior secured term loan facility in the amount of $25.0 million, which proceeds were used to repay all existing debt. In July 2017, the Company repaid the Term Loan with Silicon Valley Bank, along with the $625,000 end-of-term fee and $500,000 prepayment fee.

The Term Loans’ prepayment and end of term fees of $1.1 million were recorded as a loss on extinguishment of debt, along with $41,000 of deferred loan issuance fees, partially offset by $267,000 of end of term fees previously amortized, netting to a loss of $900,000. As of the payoff date, the Company was in compliance with all covenants.

The Company recognized related interest expense of $747,000 for the year ended December 31, 2017, of which $98,000 was related to the debt discount. During 2016, the Company recognized interest expense of $1.3 million for the year of which $198,000 was related to the debt discount.

Stock-Based Compensation

12 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

Note 11. Stock-Based Compensation

Stock Incentive Plans

The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”).

In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The ISOs and NSOs will be granted at a price per share not less than the fair value at the date of grant. Options granted generally vest over a four-year period, with 25% vesting at the end of one year and the remaining vesting monthly thereafter. Options granted, once vested, are generally exercisable for up to 10 years, after grant.

As of December 31, 2017, a total of 395,808 shares of common stock were reserved for issuance under the 2015 Plan, of which 224,647 shares of common stock are available for future grant. As of December 31, 2017, a total of 116,949 and 171,181 options are outstanding under the 2006 and 2015 Plans, respectively.

The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share):

	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2015		171,375		$	75.20	$	3,707
Options granted		89,970			103.50
Options exercised		(11,407	)		23.63
Options cancelled and forfeited		(20,999	)		89.84
Outstanding — Balance at December 31, 2016		228,939		$	87.60	$	—
Options granted		111,336			13.47
Options exercised		—			—
Options cancelled and forfeited		(52,146	)		61.60
Outstanding — Balance at December 31, 2017		288,129			63.62	$	—
Vested and expected to vest — December 31, 2017		282,394			63.95	$	—
Exercisable —December 31, 2017		144,743		$	79.53	$	—

Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock determined by the Board of Directors for each of the respective periods. The intrinsic value of options exercised was $0 for the year ended December 31, 2016. There were not any options exercised during 2017.

At December 31, 2017 and 2016, there were no expired options, and the total fair value of shares vested during the years was $449,000 and $283,000, respectively.

As of December 31, 2017, there was $1.1 million of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 2.74 years.

In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.

Expected Term—The expected term is the estimated period of time outstanding for stock options granted and was estimated based on historical, as well as anticipated future, exercise activity.

Expected Volatility—Since the Company was privately held and does not have a long trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. When selecting comparable publicly traded biotechnology companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

Risk-Free Interest Rate—The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted.

Expected Dividend—The expected dividend yield is based on the Company’s expectation of future dividend payouts to common stockholders.

The fair value of stock option awards to employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption:

	Year Ended December 31,
Assumptions	2017		2016
Expected term (years)		6.12		6.06
Expected volatility	79%		92%
Risk-free interest rate	1.90%		1.76%
Expected dividend yield		—		—

The weighted- average, estimated grant-date fair value of employee stock options granted during the years ended December 31, 2017 and 2016 was $9.20 and $22.60, respectively. The Company recognized $1.5 million and $1.1 million of compensation expense for stock options to employees and board members for the years ended December 31, 2017 and 2016, respectively.

Employee Stock Purchase Plan

The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016, the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. As of December 31, 2017, the number of shares of common stock reserved for future issuance under the ESPP is 69,270. The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of December 31, 2017, 5,731 shares had been issued under the ESPP. The Company recorded $13,000 and $80,000 of ESPP related compensation expense for the years ended December 31, 2017 and 2016, respectively.

Commitment and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 12. Commitments and Contingencies

Leases

The Company leases office and laboratory space, greenhouse space, grain storage bins, warehouse space, and equipment under operating lease agreements having initial lease terms ranging from three to five years, including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. Future minimum payments under non-cancelable operating leases in effect as of December 31, 2017, are presented below (in thousands):

Years Ending December 31,	Amounts
2018		422
2019		77
2020		72
Total future minimum payments under non- cancelable operating leases	$	571

Rent expense under all operating leases totaled $1.2 and $1.3 million for years ended December 31, 2017 and 2016, respectively.

Legal Matters

From time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. As of December 31, 2017 and 2016, the Company was not involved in any material legal proceedings.

Contingent Liability Related to the Anawah Acquisition

On June 15, 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. (“Anawah”), to purchase the Anawah’s food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs thus, the contingent liability was reduced to $3.0 million. During the third quarter of 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. As of December 31, 2017, the Company continues to pursue a total of three development programs using this technology and believes that the contingent liability is probable. As a result, $3.0 million remains on the Consolidated Balance Sheet as an other noncurrent liability.

Contracts

The Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable.

The Company licenses certain technologies via executed agreements (“In-Licensing Agreements”) that are used to develop and advance the Company’s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2% to 15% of net revenue amounts as defined in the In-Licensing Agreements will be due.

Royalties due to both related and unrelated parties on license revenue accrued as of December 31, 2017 and 2016 were $206,000 and $201,000, respectively. Royalties are included within research and development on the Consolidated Statements of Operations and Comprehensive Loss.

Milestone payments are contingent upon the successful development or implementation of various technologies. Payments for milestones yet to be achieved totaled $2.0 million for both years ended December 31, 2017 and 2016. The timing of the payments is not determinable at this time pending research and development currently in progress; however, no significant payments were made during the years ended December 31, 2017 and 2016.

The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractor’s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. While the Company’s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. There currently are routine audits in process relating to government grant revenues.

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

Note 13. Income Taxes

The components of loss before income taxes are as follows (in thousands):

	Year Ended December 31,
	2017			2016
Domestic	$	(15,681	)	$	(19,599	)
Foreign		—			—
Loss before income taxes	$	(15,681	)	$	(19,599	)

The components of the provision for income taxes for the years ended December 31, 2017 and 2016 are as follows (in thousands):

	Year Ended December 31,
	2017		2016
Current:
Federal	$	—	$	—
State		2		1
Foreign		24		24
Total current tax expense		26		25
Deferred:
Federal		—		—
State		—		—
Foreign		—		—
Total deferred tax benefit		—		—
Total tax expense	$	26	$	25

The Company operates in only one federal jurisdiction, the United States. The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:

	Year Ended December 31,
	2017			2016
Expected income tax provision at the federal statutory rate		34.0	%		34.0	%
State taxes, net of federal benefit		2.6	%		4.7	%
Change in valuation allowance		91.4	%		(37.8	)%
Nondeductible expenses		0.1	%		(0.9	)%
Impact of change in federal tax rate		(124.6	)%		—
Withholding taxes		(0.2	)%		(0.1	)%
Other		(3.5	)%		—
Income tax provision		(0.2	)%		(0.1	)%

The total income tax expense for the years ended December 31, 2017 and 2016 was $26,000 and $25,000, respectively, and is comprised of current state taxes and foreign taxes withheld by governmental agencies outside of the United States.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, net operating loss carryforwards (“NOLs”) and other tax credits. Significant components of the Company’s deferred tax assets are as follows (in thousands):

	As of December 31,
	2017			2016
Deferred tax assets:
Net operating loss carryforwards	$	37,498		$	49,593
Unearned revenue		783			1,501
Stock-based compensation		2,273			2,861
Accrued payroll and benefits		51			215
Research and development credits		171			143
Capital loss carryover		—			13
Fixed asset basis difference		128			191
Inventory reserve		396			1,110
Charitable contributions		3			5
Total deferred tax assets		41,303			55,632
Less valuation allowance		(41,303	)		(55,632	)
Net deferred tax assets	$	—		$	—

Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been offset by a valuation allowance. The net valuation allowance decreased by $14.3 million and increased by $8.5 million during the years ended December 31, 2017 and 2016, respectively.

On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21%, effective for tax years beginning after December 31, 2017. We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. As a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Act, we revalued our ending net deferred tax assets at December 31, 2017, which were fully offset by a valuation allowance. The Company has evaluated the other changes resulting from the Tax Act and does not expect them to have a material impact on the tax provision, therefore, the Company considers the accounting complete.

At December 31, 2017, the Company had federal and state NOLs aggregating approximately $152.9 million and $105.3 million, respectively. At December 31, 2017, the utilization of a portion of our NOLs is subject to an annual limitation under Section 382 of the Internal Revenue Code (IRC). Of the $152.9 million generated, $7.2 million will not be available to be utilized within the carryforward period. If not utilized, these federal NOLs will begin to expire in 2020 and these state NOLs began to expire in 2017. The Company continues to evaluate IRC Section 382, which may limit NOLs generated in future years.

The Company evaluates deferred tax assets, including the benefit from NOLs, to determine if a valuation allowance is required. Such evaluation is based on consideration of all available evidence using a “more likely than not” standard with significant weight being given to evidence that can be objectively verified. This assessment considers, among other matters, the nature, frequency, and severity of current and cumulative losses; forecasts of future profitability; the length of statutory carryforward periods; the Company’s experience with operating losses; and tax-planning alternatives. The significant piece of objective negative evidence evaluated was the cumulative loss incurred through the year ended December 31, 2017. Given this evidence and the expectation to incur operating losses in the foreseeable future, a full valuation allowance has been recorded against the net deferred tax asset. The Company will continue to maintain a full valuation allowance against the entire amount of its net deferred tax asset, until such time as the Company has determined that the weight of the objectively verifiable positive evidence exceeds that of the negative evidence and it is likely that the Company will be able to utilize all of its net deferred tax asset relating to its federal and state NOL carryforwards. Although the Company has established a full valuation allowance on its net deferred tax asset, it has not forfeited the right to carryforward tax losses up to 20 years and apply such tax losses against taxable income in such years, thereby reducing its future tax obligations. The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2017, the Company’s tax years for 2000 through 2017 are generally subject to examination by the tax authorities. The years are open back to 2000 to the extent the NOLs being carried forward were generated then.

The Company applies the provisions of ASC 740 related to accounting for uncertain tax positions and concluded there were no such positions associated with the Company requiring accrual of a liability. As of December 31, 2017, the Company has not accrued for any such positions. The Company is currently not under audit for federal or state tax purposes. The Company does not expect a significant change to occur within the next 12 months.

Retirement Benefits	12 Months Ended
Retirement Benefits	Dec. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Retirement Benefits	Note 14. Retirement Benefits The Company has a 401(k) retirement plan (the “Plan”) available for participation by all regular full-time employees who have completed three months of service with the Company. The Company established the Plan in 2008. The Plan provides for a discretionary matching contribution equal to 50% of the amount of the employee’s salary deduction, not to exceed 3% of the salary per employee. Highly compensated employees are excluded from receiving any discretionary matching contribution. Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment. The Company has the option to make discretionary matching contributions. The Company did not make discretionary matching contributions during the years ended December 31, 2017 and 2016.

Segment Reporting

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Segment and Geographic Information

Note 15. Segment and Geographic Information

Management has determined that it has one business activity and operates in one segment as it only reports financial information on an aggregate and consolidated basis to its Chief Executive Officer, who is the Company’s chief operating decision maker.

Revenues based on the location of the customers, are as follows (in thousands):

	Year Ended December 31,
	2017		2016
United States	$	1,588	$	2,715
India (1)		1,064		(100	)
Africa		315		353
France		220		18
Canada		181		202
China		586		—
Belgium		72		—
Total	$	4,026	$	3,188

(1)	The negative amount is due to the change in estimated commercialization dates in 2016, which impacted the timing of revenue recognition.

Net Loss per Share

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Net Loss per Share

Note 16. Net Loss per Share

Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weightedaverage number of common shares outstanding during the period and excludes any dilutive effects of stockbased awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. As the Company had net losses for the years ended December 31, 2017 and 2016, all potentially dilutive common shares were determined to be antidilutive.

Securities that were not included in the diluted per share calculations because they would be antidilutive were as follows (in shares):

	Year Ended December 31,
	2017		2016
Options to purchase common stock		288,129		228,939
Warrants to purchase common stock		66,845		66,845
Total		354,974		295,784

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 17. Related Party Transactions The Company’s related parties include MCC and Blue Horse Labs, Inc. (“BHL”). BHL is deemed a related party of the Company because MCC, the Company’s controlling stockholder, and BHL have some common officers and directors. Transactions with related parties are reflected in the consolidated financial statements under amounts due to related parties and notes payable to related party. Outlined below are details of agreements between the Company and its related parties: Under a license agreement executed in 2003 and amended in 2009, BHL receives a singledigit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding from BHL. Royalty fees due to BHL were $29,000 and $30,000 as of December 31, 2017 and December 31, 2016, respectively, and are included in the Consolidated Balance Sheets as amounts due to related parties.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 18. Subsequent Event On February 7, 2018, the Company received a letter from Nasdaq, indicating the Company has regained compliance with Listing Rule 5450(a)(1). On February 14, 2017, Nasdaq notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, Nasdaq determined that for 10 consecutive business days, from January 24, 2018 to February 6, 2018, the closing bid price of the Company’s common stock has been at $1.00 per share or greater and this matter is now closed. On March 19, 2018, the Company entered into definitive securities purchase agreements with institutional investors in connection with a private placement of common stock and warrants in the amount of $10 million, exclusive of any related transaction fees. The number of shares to be issued and at what price are variable and subject to the terms of the agreement. The offering is expected to close on or about March 21, 2018, subject to satisfaction of customary closing conditions.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Organization

Arcadia Biosciences, Inc. (the "Company"), was incorporated in the state of Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, and American Falls, Idaho. The Company was reincorporated in Delaware in March 2015.

The Company is a consumer-driven, agricultural food ingredient company. We aim to create value across the agricultural production and supply chain beginning with enhanced crop productivity for farmers and ultimately delivering accelerated innovation in nutritional quality consumer foods. We use state of the art gene-editing technology and advanced breeding techniques to naturally enhance the nutritional quality of grains and oilseeds to address the rapidly evolving trends in consumer health and nutrition. In addition, we have developed a broad pipeline of high value crop productivity traits designed to enhance farmer economics.

In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 7), which is jointly owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca, which is consolidated by the Company, was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies.

Reverse Stock Split

In January 2018, the Company’s board of directors approved a reverse split of 1:20 on the Company’s issued and outstanding common stock. In January 2018, the Company’s stockholders approved the certificate of amendment, which the Company filed on January 23, 2018 with the Secretary of State of Delaware to effect the reverse split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statement have been retroactively adjusted to reflect the reverse stock split for all periods presented.

Liquidity, Capital Resources, and Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2017, the Company had an accumulated deficit of $167.3 million, cash and cash equivalents of $9.1 million, and short-term investments of $3.9 million. As is disclosed in Note 10, the Company repaid its $25.0 million term loan and related interest, prepayment and end-of-term payments totaling $1.3 million with Silicon Valley Bank in July 2017. The Company believes that its existing cash, cash equivalents and investments will be insufficient to meet its anticipated cash requirements for at least through March 2019, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management’s plans include attempting to secure additional funding through equity or debt financings, sales or out-licensing of intellectual property assets, seeking partnerships with other agriculture biotechnology companies or third parties to co-develop and fund research, development or commercialization efforts, or similar transactions. There is no assurance that the Company will be successful in obtaining the necessary funding to meet its business objectives.

Basis of Presentation and Principles of Consolidation

Use of Estimates

Cash and Cash Equivalents

Investments in Equity and Debt Securities

Other-than-Temporary Impairments on Investment

Accounts Receivable

SONOVA® Gamma Linolenic Acid ("GLA") Safflower Oil Inventory

SONOVA® Gamma Linolenic Acid (“GLA”) Safflower Oil Inventory

	As of December 31,
	2017		2016
Raw Materials	$	45	$	44
Finished Goods		1,352		1,535
Inventories	$	1,397	$	1,579

Property and Equipment

Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets:

	Years
Laboratory equipment	5
Software and computer equipment	3
Furniture and fixtures	7
Vehicles	5
Leasehold improvements	2-10	*

*	Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.

Impairment of Long-Lived Assets

Fair Value of Financial Instruments

•

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

•

Level 3 inputs are unobservable inputs for the asset or liability.

Concentration of Risk

Customer Concentration

Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date.

Customers representing greater than 10% of accounts receivable were as follows (in percentages):

	As of December 31,
	2017		2016
Customer A		18		—
Customer D		53		—
Customer E		24		36
Customer H		—		27
Customer I		—		22

Customers representing greater than 10% of total revenues were as follows (in percentages):

	For Year Ended December 31,
	2017		2016
Customer A		26		—
Customer D		18		30
Customer G		2		21
Customer J		8		11
Customer K		14		—

Stock-Based Compensation

Contract Research Revenues

Government Grant Revenues

Unearned Revenue

The Company defers revenue to the extent that cash received in conjunction with a license agreement, contract or grant exceeds the revenue recognized in accordance with Company policies.

Research and Development Expenses

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Line Items]

Summary of Inventories

Inventories consist of the following (in thousands):

	As of December 31,
	2017		2016
Raw Materials	$	45	$	44
Finished Goods		1,352		1,535
Inventories	$	1,397	$	1,579

Summary of Average Estimated Useful Lives of Assets

Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets:

	Years
Laboratory equipment	5
Software and computer equipment	3
Furniture and fixtures	7
Vehicles	5
Leasehold improvements	2-10	*

*	Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.

Customer Concentration Risk [Member]

Accounting Policies [Line Items]

Summary of Customer Concentration

Customers representing greater than 10% of accounts receivable were as follows (in percentages):

	As of December 31,
	2017		2016
Customer A		18		—
Customer D		53		—
Customer E		24		36
Customer H		—		27
Customer I		—		22

Customers representing greater than 10% of total revenues were as follows (in percentages):

	For Year Ended December 31,
	2017		2016
Customer A		26		—
Customer D		18		30
Customer G		2		21
Customer J		8		11
Customer K		14		—

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Summary of Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	As of December 31,
	2017			2016
Laboratory equipment	$	2,404		$	2,632
Software and computer equipment		424			449
Furniture and fixtures		147			153
Vehicles		203			204
Leasehold improvements		2,002			1,991
Assets under construction		—			20
Property and equipment, gross		5,180			5,449
Less accumulated depreciation and amortization		(4,881	)		(4,941	)
Property and equipment, net	$	299		$	508

Investments and Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2017

Investments And Fair Value Measurements [Abstract]

Summary of Amortized Cost and Fair Value of the Available-For-Sale Investment Securities Portfolio

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
December 31, 2017
Cash equivalents:
Money market funds	$	8,943	$	—	$	—		$	8,943
Short-term investments:
Commercial paper		1,399		—		—			1,399
U.S. government securities		2,500		—		(1	)		2,499
Total Assets at Fair Value	$	12,842	$	—	$	(1	)	$	12,841

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
December 31, 2016
Cash equivalents:
Money market funds	$	1,549	$	—	$	—		$	1,549
Short-term investments:
Certificates of Deposit		3,049		—		(2	)		3,047
Commercial paper		21,248		—		—			21,248
U.S. government securities		19,267		—		(9	)		19,258
U.S. government agency securities		5,000		—		(6	)		4,994
Long-term investments:
U.S. government securities		2,500		—		(2	)		2,498
Total Assets at Fair Value	$	52,613	$	—	$	(19	)	$	52,594

Summary of Fair Value of Available-for-Sale Investments

The fair value of the available-for-sale investments at December 31, 2017 were as follows:

	Fair Value Measurements at December 31, 2017
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	8,943	$	—	$	—	$	8,943
Short-term investments:
Commercial paper		—		1,399		—		1,399
U.S. government securities		2,499		—		—		2,499
Total Assets at Fair Value	$	11,442	$	1,399	$	—	$	12,841

The fair value of the available-for-sale investments at December 31, 2016 were as follows:

	Fair Value Measurements at December 31, 2016
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	1,549	$	—	$	—	$	1,549
Short-term investments:
Certificates of Deposit		—		3,047		—		3,047
Commercial paper		—		21,248		—		21,248
U.S. government securities		19,258		—		—		19,258
U.S. government agency securities		—		4,994		—		4,994
Long-term investments:
U.S. government securities		2,498		—		—		2,498
Total Assets at Fair Value	$	23,305	$	29,289	$	—	$	52,594

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Investment in Unconsolidated Entity (Tables)

12 Months Ended

Dec. 31, 2017

Limagrain Cereal Seeds LLC [Member]

Summary of Condensed Financial Information Related to Unconsolidated Entity

Summarized condensed financial information related to the unconsolidated entity, accounted for using the equity method is as follows (in thousands):

	As of and for the year ended December 31,
	2017 (3)			2016
Assets:
Current assets	$	—		$	2,963
Non-current assets		—			9,776
Total assets		—			12,739
Liabilities and equity:
Current liabilities		—			26,992
Equity of Arcadia Biosciences, Inc.(1)		—			(4,989	)
Equity of VUSA		—			(9,264	)
Total liabilities and equity	$	—		$	12,739
Revenue	$	216		$	3,635
Gross profit		118			1,594
Loss from continuing operations		(1,422	)		(5,268	)
Net loss (2)		(1,539	)		(5,413	)

(1)	Effective June 2014, the investment balance was reduced to $0.

(2)	As the Company’ investment balance was reduced to $0 in 2014, the Company’s share of the pretax loss is $0 for the years ended December 31, 2017 and 2016.

(3)	Represents year to date activity through transaction date of March 31, 2017.

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Summary of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following (in thousands):

	As of December 31,
	2017		2016
Accounts payable—trade	$	366	$	222
Payroll and benefits		805		1,331
Research and development		899		182
Royalty fees due to unrelated parties		177		170
Accrued interest on notes payable		—		98
Consulting		32		29
Rent and utilities		51		85
Legal		83		45
Accrued withholding taxes		24		—
Other		59		197
Total accounts payable and accrued expenses	$	2,496	$	2,359

Long-Term Debt and Other Financing Arrangements (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Summary of Long-Term Debt

There was no long-term debt as of the year ended December 31, 2017. Longterm debt as of the year ended December 31, 2016 consisted of the following (in thousands):


Notes payable	$	25,127
Total	$	25,127
Less current portion		—
Long-term portion	$	25,127

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Activity Under Stock Incentive Plans

The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share):

	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2015		171,375		$	75.20	$	3,707
Options granted		89,970			103.50
Options exercised		(11,407	)		23.63
Options cancelled and forfeited		(20,999	)		89.84
Outstanding — Balance at December 31, 2016		228,939		$	87.60	$	—
Options granted		111,336			13.47
Options exercised		—			—
Options cancelled and forfeited		(52,146	)		61.60
Outstanding — Balance at December 31, 2017		288,129			63.62	$	—
Vested and expected to vest — December 31, 2017		282,394			63.95	$	—
Exercisable —December 31, 2017		144,743		$	79.53	$	—

Weighted-Average Fair Value Assumption of Stock Option Awards

The fair value of stock option awards to employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption:

	Year Ended December 31,
Assumptions	2017		2016
Expected term (years)		6.12		6.06
Expected volatility	79%		92%
Risk-free interest rate	1.90%		1.76%
Expected dividend yield		—		—

Commitment and Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Schedule of Future Minimum Payments Under Non-Cancelable Operating Leases

Future minimum payments under non-cancelable operating leases in effect as of December 31, 2017, are presented below (in thousands):

Years Ending December 31,	Amounts
2018		422
2019		77
2020		72
Total future minimum payments under non- cancelable operating leases	$	571

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Components of Loss Before Income Taxes

The components of loss before income taxes are as follows (in thousands):

	Year Ended December 31,
	2017			2016
Domestic	$	(15,681	)	$	(19,599	)
Foreign		—			—
Loss before income taxes	$	(15,681	)	$	(19,599	)

Provision for Income Taxes

The components of the provision for income taxes for the years ended December 31, 2017 and 2016 are as follows (in thousands):

	Year Ended December 31,
	2017		2016
Current:
Federal	$	—	$	—
State		2		1
Foreign		24		24
Total current tax expense		26		25
Deferred:
Federal		—		—
State		—		—
Foreign		—		—
Total deferred tax benefit		—		—
Total tax expense	$	26	$	25

Reconciliation of the Statutory Federal Income Tax Rate

The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:

	Year Ended December 31,
	2017			2016
Expected income tax provision at the federal statutory rate		34.0	%		34.0	%
State taxes, net of federal benefit		2.6	%		4.7	%
Change in valuation allowance		91.4	%		(37.8	)%
Nondeductible expenses		0.1	%		(0.9	)%
Impact of change in federal tax rate		(124.6	)%		—
Withholding taxes		(0.2	)%		(0.1	)%
Other		(3.5	)%		—
Income tax provision		(0.2	)%		(0.1	)%

Deferred Tax Assets and Liabilities

Significant components of the Company’s deferred tax assets are as follows (in thousands)

	As of December 31,
	2017			2016
Deferred tax assets:
Net operating loss carryforwards	$	37,498		$	49,593
Unearned revenue		783			1,501
Stock-based compensation		2,273			2,861
Accrued payroll and benefits		51			215
Research and development credits		171			143
Capital loss carryover		—			13
Fixed asset basis difference		128			191
Inventory reserve		396			1,110
Charitable contributions		3			5
Total deferred tax assets		41,303			55,632
Less valuation allowance		(41,303	)		(55,632	)
Net deferred tax assets	$	—		$	—

Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Summary of Revenues Based on Location of Customers

Revenues based on the location of the customers, are as follows (in thousands):

	Year Ended December 31,
	2017		2016
United States	$	1,588	$	2,715
India (1)		1,064		(100	)
Africa		315		353
France		220		18
Canada		181		202
China		586		—
Belgium		72		—
Total	$	4,026	$	3,188

Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Schedule of Securities Not Included in Diluted per Share Calculations

Securities that were not included in the diluted per share calculations because they would be antidilutive were as follows (in shares):

	Year Ended December 31,
	2017		2016
Options to purchase common stock		288,129		228,939
Warrants to purchase common stock		66,845		66,845
Total		354,974		295,784

Description of Business - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Description Of Business [Line Items]
Place of incorporation		Arizona
Year of incorporation		2002
Place of reincorporation		Delaware
Date of reincorporation		2015-03
Reverse split of issued and outstanding common stock		1:20
Accumulated deficit		$ 167,257	$ 151,550
Cash and cash equivalents		9,125	2,013	$ 23,973
Short-term investments		$ 3,898	$ 48,547
Senior Secured Term Loan Facility [Member]
Description Of Business [Line Items]
Repayment of term loan	$ 25,000
Interest paid, prepayment and end-of-term payments	$ 1,300

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2014
Accounting Policies [Line Items]
Reserved for doubtful accounts	$ 0	$ 0
Write-down of inventory	0	500,000
Impairment of long-lived assets	$ 0	0
Maximum [Member]
Accounting Policies [Line Items]
Cost method investment ownership percentage	20.00%
Limagrain Cereal Seeds LLC [Member]
Accounting Policies [Line Items]
Equity method investments	$ 0	0	$ 0
Impairment of equity method investments	0	0
Verdeca LLC
Accounting Policies [Line Items]
VIEs Operations	0	0
VIEs assets or liability	$ 0	$ 0

Summary of Significant Accounting Policies - Summary of Average Estimated Useful Lives of Assets (Detail)	12 Months Ended
	Dec. 31, 2017
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	7 years
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Leasehold improvements [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Leasehold improvements [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	10 years

Summary of Significant Accounting Policies - Summary of Customer Concentration (Detail) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounts Receivable [Member] \| Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	18.00%
Accounts Receivable [Member] \| Customer D [Member]
Concentration Risk [Line Items]
Concentration risk percentage	53.00%
Accounts Receivable [Member] \| Customer E [Member]
Concentration Risk [Line Items]
Concentration risk percentage	24.00%	36.00%
Accounts Receivable [Member] \| Customer H [Member]
Concentration Risk [Line Items]
Concentration risk percentage		27.00%
Accounts Receivable [Member] \| Customer I [Member]
Concentration Risk [Line Items]
Concentration risk percentage		22.00%
Total Revenue [Member] \| Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	26.00%
Total Revenue [Member] \| Customer D [Member]
Concentration Risk [Line Items]
Concentration risk percentage	18.00%	30.00%
Total Revenue [Member] \| Customer G [Member]
Concentration Risk [Line Items]
Concentration risk percentage	2.00%	21.00%
Total Revenue [Member] \| Customer J [Member]
Concentration Risk [Line Items]
Concentration risk percentage	8.00%	11.00%
Total Revenue [Member] \| Customer K
Concentration Risk [Line Items]
Concentration risk percentage	14.00%

Recent Accounting Pronouncements- Additional Information (Detail) $ in Millions	Dec. 31, 2017 USD ($)
Up-Front License Fees [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Unearned revenues	$ 2.4

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 5,180	$ 5,449
Less accumulated depreciation and amortization	(4,881)	(4,941)
Property and equipment, net	299	508
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,404	2,632
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	424	449
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	147	153
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	203	204
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,002	1,991
Assets under construction [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross		$ 20

Investments and Fair Value Measurements - Summary of Amortized Cost and Fair Value of the Available-For-Sale Investment Securities Portfolio (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 12,842	$ 52,613
Unrealized Gains		0
Unrealized Losses	(1)	(19)
Estimated Fair Value	12,841	52,594
Cash Equivalents [Member] \| Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	8,943	1,549
Unrealized Gains		0
Unrealized Losses		0
Estimated Fair Value	8,943	1,549
Short-term Investments [Member] \| Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	1,399	21,248
Unrealized Gains		0
Unrealized Losses		0
Estimated Fair Value	1,399	21,248
Short-term Investments [Member] \| U.S. Government Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	2,500	19,267
Unrealized Gains		0
Unrealized Losses	(1)	(9)
Estimated Fair Value	$ 2,499	19,258
Short-term Investments [Member] \| Certificates of Deposit [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		3,049
Unrealized Gains		0
Unrealized Losses		(2)
Estimated Fair Value		3,047
Short-term Investments [Member] \| U.S. Government Agency Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		5,000
Unrealized Gains		0
Unrealized Losses		(6)
Estimated Fair Value		4,994
Long-term investments [Member] \| U.S. Government Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		2,500
Unrealized Gains		0
Unrealized Losses		(2)
Estimated Fair Value		$ 2,498

Investments and Fair Value Measurements - Summary of Fair Value of Available-for-Sale Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets at Fair Value
Total Assets at Fair Value	$ 12,841	$ 52,594
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	8,943	1,549
Commercial Paper [Member]
Assets at Fair Value
Short-term investments	1,399	21,248
U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments	2,499	19,258
Long-term investments		2,498
Certificates of Deposit [Member]
Assets at Fair Value
Short-term investments		3,047
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	11,442	23,305
Level 1 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	8,943	1,549
Level 1 [Member] \| Commercial Paper [Member]
Assets at Fair Value
Short-term investments	0	0
Level 1 [Member] \| U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments	2,499	19,258
Long-term investments		2,498
Level 1 [Member] \| Certificates of Deposit [Member]
Assets at Fair Value
Short-term investments		0
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	1,399	29,289
Level 2 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 2 [Member] \| Commercial Paper [Member]
Assets at Fair Value
Short-term investments	1,399	21,248
Level 2 [Member] \| U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments	0	0
Long-term investments		0
Level 2 [Member] \| Certificates of Deposit [Member]
Assets at Fair Value
Short-term investments		3,047
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Level 3 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 3 [Member] \| Commercial Paper [Member]
Assets at Fair Value
Short-term investments	0	0
Level 3 [Member] \| U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments	$ 0	0
Long-term investments		0
Level 3 [Member] \| Certificates of Deposit [Member]
Assets at Fair Value
Short-term investments		0
U.S. Government Agency Securities [Member]
Assets at Fair Value
Short-term investments		4,994
U.S. Government Agency Securities [Member] \| Level 1 [Member]
Assets at Fair Value
Short-term investments		0
U.S. Government Agency Securities [Member] \| Level 2 [Member]
Assets at Fair Value
Short-term investments		4,994
U.S. Government Agency Securities [Member] \| Level 3 [Member]
Assets at Fair Value
Short-term investments		$ 0

Investment in Unconsolidated Entity - Additional information (Detail) - USD ($)		12 Months Ended
	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2014
Vilmorin Cie [Member]
Schedule of Equity Method Investments [Line Items]
Investment, remaining ownership percentage			65.00%
Limagrain Cereal Seeds LLC [Member]
Schedule of Equity Method Investments [Line Items]
Investment, ownership percentage			35.00%
Loss on investments			$ 0
Equity Method Investment, Additional Information		At December 31, 2016, the Company owned a 35% ownership position in Limagrain Cereal Seeds LLC (“LCS”). The remaining 65% of LCS was owned by Vilmorin & Cie (“Limagrain”), a major global producer and marketer of field crop and vegetable seeds, through its wholly owned subsidiary, Vilmorin USA (“VUSA”). LCS improves and develops new wheat and barley varieties utilizing genetic and breeding resources, as well as advanced technologies, from Limagrain and the Company. Historically, funding for LCS has come from an initial pro rata equity investment from each partner and with subsequent financing in the form of debt from VUSA. As of December 31, 2016, the Company’s investment in LCS had been reduced to $0 as a result of its equity method loss recognition.
Common stock shares retired using cost method as result of transfer of membership interest	92,194
Equity method investments		$ 0	$ 0	$ 0
Unconsolidated Entity [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investments		$ 0

Investment in Unconsolidated Entity - Summary of Condensed Financial Information Related to Unconsolidated Entity (Detail) - Limagrain Cereal Seeds LLC [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Assets:
Current assets		$ 2,963
Non-current assets		9,776
Total assets		12,739
Liabilities and equity:
Current liabilities		26,992
Total liabilities and equity		12,739
Revenue	$ 216	3,635
Gross profit	118	1,594
Loss from continuing operations	(1,422)	(5,268)
Net loss	$ (1,539)	(5,413)
Arcadia Biosciences, Inc [Member]
Liabilities and equity:
Equity		(4,989)
Vilmorin USA [Member]
Liabilities and equity:
Equity		$ (9,264)

Investment in Unconsolidated Entity - Summary of Condensed Financial Information Related to Unconsolidated Entity (Parenthetical ) (Detail) - Limagrain Cereal Seeds LLC [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2016	Jun. 30, 2014
Schedule of Equity Method Investments [Line Items]
Equity method investments	$ 0		$ 0	$ 0
Share of pretax loss	$ 0	$ 0

Variable Interest Entity - Additional Information (Detail)	1 Months Ended		12 Months Ended				20 Months Ended
	Sep. 30, 2014 USD ($) shares	Feb. 29, 2012 Soybean_Grower	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) shares	Dec. 31, 2014 USD ($)	Aug. 31, 2014 USD ($)
Variable Interest Entity [Line Items]
Variable interest entity agreement, terms			Both the Company and Bioceres incur expenses in support of specific activities agreed, as defined by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. An agreement executed in conjunction with the formation of Verdeca specified that if Bioceres determines it requires cash to fund its contributed services (subject to certain annual limits), Bioceres, S.A. may elect to sell shares of its common stock to the Company for an amount not exceeding $5.0 million in the aggregate over a four-year period.
Funding period of cash required for contributed services			4 years
Aggregate value of common stock purchased							$ 2,000,000
Number of shares surrendered \| shares	1,832
Research agreement settled					$ 205,000
Number of share remaining \| shares					632
Fair value of share held					$ 500,000
Cost method investment					$ 0
Direct and allocated overhead amount			$ 912,000	$ 416,000
Research And Development Expense [Member]
Variable Interest Entity [Line Items]
VIE agreement amendment expense						$ 1,500,000
Amended Purchase Commitment Of Common Stock [Member]
Variable Interest Entity [Line Items]
Commitment to purchase stock in 2014	$ 500,000
Maximum [Member]
Variable Interest Entity [Line Items]
Commitment to purchase stock			5,000,000
Maximum [Member] \| Purchase Commitment of Common Stock [Member]
Variable Interest Entity [Line Items]
Commitment to purchase stock in 2014			2,000,000
Commitment to purchase stock in 2015			$ 1,200,000
Bioceres, S.A. [Member]
Variable Interest Entity [Line Items]
Number of soybean growers owned \| Soybean_Grower		300

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Accounts payable—trade	$ 366	$ 222
Payroll and benefits	805	1,331
Research and development	899	182
Royalty fees due to unrelated parties	177	170
Accrued interest on notes payable	0	98
Consulting	32	29
Rent and utilities	51	85
Legal	83	45
Accrued withholding taxes	24	0
Other	59	197
Total accounts payable and accrued expenses	$ 2,496	$ 2,359

Accounts Payable and Accrued Expenses - Exit or Disposal Activities - Additional Information (Details)	12 Months Ended
	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) Position
Payables And Accruals [Line Items]
Number of positions eliminated \| Position		23
Other restructuring costs	$ 0	$ 0
One-Time Employee Termination Benefits [Member]
Payables And Accruals [Line Items]
Severance cost accrued under payroll and benefits		389,000
One-Time Employee Termination Benefits [Member] \| Selling, General, and Administrative Expense [Member]
Payables And Accruals [Line Items]
Severance costs		192,000
Executive Employment Contract [Member] \| Selling, General, and Administrative Expense [Member]
Payables And Accruals [Line Items]
Severance costs		$ 224,000

Long-Term Debt and Other Financing Arrangements - Summary of Long-Term Debt (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Notes payable		$ 25,127,000
Total	$ 0	25,127,000
Less current portion		0
Long-term portion		$ 25,127,000

Long-Term Debt and Other Financing Arrangements - Term Loan - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ (900,000)
Repayment of accrued interest and prepayment fee		747,000	$ 1,319,000
Interest expense related to debt discount		98,000	198,000
Senior Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Debt instrument, face amount				$ 25,000,000
Debt instrument end-of-term fee	$ 625,000
Debt instrument prepayment fee	$ 500,000
Loss on extinguishment of debt		(1,100,000)
Deferred loan issuance fees		41,000
Partially offset end of term fee previously amortized		267,000
Partially offset end of term fee previously amortized netting		900,000
Repayment of accrued interest and prepayment fee		747,000	1,300,000
Interest expense related to debt discount		$ 98,000	$ 198,000

Stock-Based Compensation - Additional Information (Detail)			12 Months Ended
	May 20, 2015 shares	May 14, 2015	Dec. 31, 2017 USD ($) IncentivePlan $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans \| IncentivePlan			2
Total number of options outstanding			288,129	228,939	171,375
Intrinsic value of options exercised \| $			$ 0	$ 0
Options exercised			0	11,407
Options expired in period			0	0
Total fair value of shares vested \| $			$ 449,000	$ 283,000
Unrecognized compensation cost related to unvested stock-based compensation grants \| $			$ 1,100,000
Weighted-average remaining recognition period			2 years 8 months 26 days
Weighted-average estimated grant-date fair value of stock options granted \| $ / shares			$ 9.20	$ 22.60
Stock-based compensation \| $			$ 1,474,000	$ 1,059,000
2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan			69,270
Stock-based compensation \| $			$ 13,000	$ 80,000
Percentage in payroll deductions to acquire shares of common stock		15.00%
Purchase plan offering period		6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage		85.00%
Issuance of common stock pursuant to employee stock purchase plan			5,731
First offering period, start date		May 14, 2015
First offering period, end date		Feb. 01, 2016
2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Terms under the plan			The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.
Total number of shares reserved for issuance under plan	154,387		395,808
Options vesting period	4 years
Common stock available for future grant			224,647
Total number of options outstanding			171,181
2015 Omnibus Equity Incentive Plan [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options vesting percentage at end of one year	25.00%
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan	10,637
Total number of options outstanding			116,949
Maximum [Member] \| 2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period	10 years

Stock-Based Compensation - Summary of Activity Under Stock Incentive Plans (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding, Beginning Balance	228,939	171,375
Shares Subject to Outstanding, Options granted	111,336	89,970
Shares Subject to Outstanding, Options exercised	0	(11,407)
Shares Subject to Outstanding, Options cancelled and forfeited	(52,146)	(20,999)
Shares Subject to Outstanding, Ending Balance	288,129	228,939
Shares Subject to Outstanding, Vested and expected to vest	282,394
Shares Subject to Outstanding, Exercisable	144,743
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance	$ 87.60	$ 75.20
Weighted-Average Exercise Price Per Share, Options granted	13.47	103.50
Weighted-Average Exercise Price Per Share, Options exercised		23.63
Weighted-Average Exercise Price Per Share, Options cancelled and forfeited	61.60	89.84
Weighted Average Exercise Price Per Share, Outstanding Ending Balance	63.62	$ 87.60
Weighted Average Exercise Price Per Share, Vested and expected to vest	63.95
Weighted Average Exercise Price Per Share, Exercisable	$ 79.53
Aggregate Intrinsic Value, Outstanding Balance			$ 3,707

Stock-Based Compensation - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 1 month 13 days	6 years 21 days
Expected volatility	79.00%	92.00%
Risk-free interest rate	1.90%	1.76%

Commitments and Contingencies - Additional Information (Detail)		12 Months Ended
	Dec. 31, 2010 USD ($) Program	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jun. 15, 2005 USD ($)
Commitments And Contingencies [Line Items]
Operating leases rent expense		$ 1,200,000	$ 1,300,000
Other noncurrent liability		3,000,000	3,000,000
Royalties due to both related and unrelated parties on license revenue accrued		206,000	201,000
Milestones payments yet to be achieved		2,000,000	2,000,000
Milestones payment		$ 0	$ 0
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability	$ 3,000,000			$ 5,000,000
Date of merger and reorganization		Jun. 15, 2005
Restructuring activities, description		As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs
Number of development programs ceased \| Program	3
Number of development programs \| Program	6
Other noncurrent liability		$ 3,000,000
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		3 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		2.00%
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		5 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		15.00%

Commitments and Contingencies - Future Minimum Payments Under Non-Cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2017 USD ($)
Operating Leases Future Minimum Payments Due [Abstract]
2018	$ 422
2019	77
2020	72
Total future minimum payments under non- cancelable operating leases	$ 571

Income Taxes - Components of Loss Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Domestic	$ (15,681)	$ (19,599)
Foreign	0	0
Net loss before income taxes	$ (15,681)	$ (19,599)

Income Taxes - Components of the Provision for Income Taxes (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Current:
Federal	$ 0	$ 0
State	2,000	1,000
Foreign	24,000	24,000
Total current tax expense	26,000	25,000
Deferred:
Federal	0	0
State	0	0
Foreign	0	0
Total deferred tax benefit	0	0
Total tax expense	$ 26,000	$ 25,000

Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Expected income tax provision at the federal statutory rate	34.00%	34.00%
State taxes, net of federal benefit	2.60%	4.70%
Change in valuation allowance	91.40%	(37.80%)
Nondeductible expenses	0.10%	(0.90%)
Impact of change in federal tax rate	(124.60%)	0.00%
Withholding taxes	(0.20%)	(0.10%)
Other	(3.50%)	0.00%
Income tax provision	(0.20%)	(0.10%)

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Income Tax [Line Items]
Total income tax expense		$ 26,000	$ 25,000
Net valuation allowance increased (decrease)		$ (14,300,000)	$ 8,500,000
Corporate tax rate		34.00%	34.00%
Operating loss carryforwards limitations on use		it has not forfeited the right to carryforward tax losses up to 20 years
Tax years open back to extent of NOLs being carried forward		2000
Uncertain Tax Position		$ 0
Federal [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss		152,900,000
Operating loss carryforward generated		152,900,000
Operating loss carryforward unutilized		7,200,000
State [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss		$ 105,300,000
Maximum [Member]
Schedule Of Income Tax [Line Items]
Corporate tax rate		35.00%
Right to carryforward tax losses, period		20 years
Tax year subject to examination by the tax authorities		2017
Minimum [Member]
Schedule Of Income Tax [Line Items]
Tax year subject to examination by the tax authorities		2000
Scenario Plan [Member]
Schedule Of Income Tax [Line Items]
Corporate tax rate	21.00%

Income Taxes - Summary of Company's Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carryforwards	$ 37,498	$ 49,593
Unearned revenue	783	1,501
Stock-based compensation	2,273	2,861
Accrued payroll and benefits	51	215
Research and development credits	171	143
Capital loss carryover	0	13
Fixed asset basis difference	128	191
Inventory reserve	396	1,110
Charitable contributions	3	5
Total deferred tax assets	41,303	55,632
Less valuation allowance	(41,303)	(55,632)
Net deferred tax assets	$ 0	$ 0

Retirement Benefits - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Compensation And Retirement Disclosure [Abstract]
Employer matching contribution, percent	50.00%
Maximum annual contribution per employee, percent	3.00%
Description of defined contribution pension and other postretirement plans	Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment.
Defined benefit plan employee vested minimum period, years	1 year
Amount accrued for company's approved discretionary match	$ 0	$ 0

Segment and Geographic Information - Summary of Revenues Based on Location of Customers (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

$ 4,026

$ 3,188

United States

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

1,588

2,715

India

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

^[1]

1,064

(100)

Africa

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

315

353

France

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

220

Canada

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

181

$ 202

China

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

586

Belgium

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

$ 72

[1]	The negative amount is due to the change in estimated commercialization dates in 2016, which impacted the timing of revenue recognition.

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	354,974	295,784
Option to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	288,129	228,939
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	66,845	66,845

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Royalty fees due	$ 29	$ 30
Blue Horse Labs Inc [Member]
Related Party Transaction [Line Items]
Royalty fees due	$ 29	$ 30

Subsequent Event - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Mar. 19, 2018	Feb. 06, 2018	Feb. 14, 2017
Subsequent Event [Line Items]
Minimum bid price common stock failed to maintain			$ 1.00
Duration of consecutive business days common stock failed to maintain minimum bid price or greater			30 days
Subsequent Event [Member]
Subsequent Event [Line Items]
Duration of consecutive business days common stock maintained minimum bid price or greater		10 days
Subsequent Event [Member] \| Private Placement Of Common Stock And Warrants [Member]
Subsequent Event [Line Items]
Common stock and warrants to be sold	$ 10
Subsequent Event [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Closing bid price of common stock		$ 1.00

Investments and Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2017 USD ($)
Investments Debt And Equity Securities [Abstract]
Investment in continuous unrealized loss position for more than twelve months	$ 0

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Summary of Significant Accounting Policies - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw Materials	$ 45	$ 44
Finished Goods	1,352	1,535
Inventories	$ 1,397	$ 1,579